Tag: NEOVACS
Neovacs announces a fundraising of 1 million euros – 03/02/2023 at 18:15
(AOF) – Néovacs announces a fundraising of 1 million euros by drawing 1 tranche of Oceane-BSA, with a nominal value of 1 million euros, subscribed by European High Growth Opportunities…
Pharnext could become an SCA controlled by Neovacs
Through Alexandra Saintpierre Published on 01/24/2023 at 2:29 p.m. Photo credit © NissierPictures …
Pharnext: an agreement governs financing by Neovacs – 01/19/2023 at 12:22
(CercleFinance.com) – Pharnext and Neovacs announced on Thursday the signing of an agreement intended to govern their financing and strategic support agreement presented at the end of 2022. This agreement…
Néovacs: raises 1 ME via the drawing of a tranche of OCEANE-BSA – 01/10/2023 at 6:21 p.m.
(CercleFinance.com) – Néovacs announces a fundraising of 1 ME by drawing 1 tranche of OCEANE-BSA, with a nominal value of 1,000,000 E, subscribed by European High Growth Opportunities Securitization Fund.…
Néovacs: raises 1 ME via the drawdown of a tranche of OCEANE-BSA bonds
(CercleFinance.com) – Néovacs announces a fundraising of 1 ME by drawing 1 tranche of OCEANE-BSA, with a nominal value of 1,000,000 E, subscribed by European High Growth Opportunities Securitization Fund.…
Pharnext: further strengthened links with Neovacs – 2022-12-29 at 12:01
(CercleFinance.com) – Pharnext shares soared on the Paris Stock Exchange on Thursday following the presentation of a series of measures aimed at ensuring the next steps in the development of…
Neovacs: reinforced support measures for Pharnext – 2022-12-29 at 13:00
(CercleFinance.com) – Neovacs, a biotechnology company specializing in therapeutic vaccines, announced Thursday that it would strengthen its ties with Pharnext in order to ensure the next stages of development of…
Pharnext strengthens its ties with Neovacs to ensure the next stages of its development – 2022-12-28 at 20:00
PARIS, France, December 28, 2022 at 8:00 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no…
NEOVACS: PHARNEXT STRENGTHENS ITS TIES WITH NEOVACS TO ENSURE THE NEXT STEPS OF ITS DEVELOPMENT – 2022-12-28 at 20:00
Paris, December 28, 2022 – 8:00 p.m. CET – Neovacs (Euronext Growth Paris: ALNEV), a French biotechnology company specializing in therapeutic vaccines targeting the treatment of autoimmune diseases and the…
Pharnext strengthens its ties with Neovacs to ensure its development – 2022-12-29 at 08:47
(AOF) – Pharnext SA, a late-stage biopharmaceutical company, today announces a series of decisions aimed at securing the next stages of its development with the support of Neovacs (a French…
NEOVACS: REDUCTION OF THE PAR VALUE OF THE SHARE – 2022/12/19 at 6:00 pm
Paris, December 19, 2022 – 6 p.m. CET – The NEOVACS Board of Directors, based on the 11 th resolution voted at the General Meeting of June 29, 2022, decided…
Neovacs reduces its capital after falling by more than 90% in three months – 12/19/2022 at 18:23
(AOF) – The Neovacs Board of Directors has decided to carry out a capital reduction, motivated by losses by way of reduction of the par value of the share. The…